Danazol treatment of endometriosis: long-term follow-up

other OA: closed public-domain-us ⤵ 1 in-corpus citation
View on PubMed View at publisher
AI-generated summary by qwen3.7-flash, 2026-08-23

Danazol treatment for pelvic endometriosis resulted in minimal side effects, symptom recurrence in 33%, and a 50% conception rate among potentially fertile patients within six months of discontinuing therapy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Forty-nine women diagnosed as having pelvic endometriosis were treated with 800 mg of danazol/day for a mean duration of 6 months. The average length of the follow-up period was 78 months. Side effects were minimal, and regular ovulatory menses returned within 25 to 90 days (average 42 days). Forty-two (85.7% of these women had associated infertility. Recurrence of symptoms was reported in 33% but in no patient were the symptoms worse than before entering the study. Of 30 patients desirous of pregnancy, 20 were potentially fertile; of these, 10 conceived within 6 months of discontinuing therapy, for a conception rate of 50%. Nine of the remaining ten patients required additional therapeutic procedures (surgery and/or danazol), and four of these conceived within 12 months. These results compare favorably with those of other investigations, since most of our patients were referred to us after being subjected to a variety of regimens, both hormonal and surgical.

My notes (saved in your browser only)

Condition tags

endometriosisinfertility

MeSH descriptors

Danazol Endometriosis Pregnadienes Danazol Danazol Endometriosis Female Follow-Up Studies Humans Pregnadienes Pregnancy Recurrence

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Cited by (1)

Source provenance

europepmc
last seen: 2026-08-29T06:12:09.280863+00:00
pubmed
last seen: 2026-05-14T05:58:48.767648+00:00
unpaywall
last seen: 2026-08-29T06:28:44.313744+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine